A Proof of Principle Study of Ondansetron for the Prevention of Vasovagal Syncope: The Eleventh Prevention of Syncope Trial (POST11) (POST 11)
Vasovagal Syncope (VVS), Syncope
About this trial
This is an interventional treatment trial for Vasovagal Syncope (VVS) focused on measuring Ondansetron
Eligibility Criteria
Inclusion Criteria: (A) ≥1 syncopal spells in the year preceding enrolment (B) ≥-2 points on the Calgary Syncope Symptom Score( Accurate Calculation for Diagnosis of Vasovagal Syncope) (C) Age ≥18 years with informed consent Exclusion Criteria: other causes of syncope, such as ventricular tachycardia, complete heart block, orthostatic hypotension or hypersensitive carotid sinus syndrome an inability to give informed consent important valvular, coronary, myocardial or conduction abnormality or significant arrhythmia hypertrophic cardiomyopathy a permanent pacemaker a seizure disorder hypertension defined as >160/90 mm Hg pregnancy lactating women glaucoma medications with known effects on BP Known hypersensitivity to ondansetron and related medications other factors which, in the investigator's opinion, would prevent the subject from completing the protocol.
Sites / Locations
- University of Calgary
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Ondansetron
Placebo
2 doses of Ondansetron 8mg PO (evening before and morning of study)
2 doses of matching placebo 8 mg PO (evening before and morning of study)